Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
Stephen J ThomasEdson D MoreiraNicholas KitchinJudith AbsalonAlejandra GurtmanStephen LockhartJohn L PerezGonzalo Pérez MarcFernando P PolackCristiano ZerbiniRuth BaileyKena A SwansonXia XuSatrajit RoychoudhuryKenneth KourySalim BouguermouhWarren V KalinaDavid CooperRobert W FrenckLaura L HammittÖzlem TüreciHaylene NellAxel SchaeferSerhat ÜnalQi YangPaul LiberatorDina B TresnanSusan MatherPhilip R DormitzerUğur ŞahinWilliam C GruberKathrin U Jansennull nullPublished in: The New England journal of medicine (2021)
Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).